Single Dose GW685698X Magnesium Stearate Study In Asthmatic Patients.
Status:
Completed
Trial end date:
2007-04-09
Target enrollment:
Participant gender:
Summary
This is a single centre, randomised, double blind, two-way crossover study, to investigate
the safety, tolerability, pharmacokinetics and pharmacodynamics of inhaled dry powder
GW685698X (800?g) containing magnesium stearate. Magnesium stearate is an excipient added to
improve the physical stability of inhaled dry powder formulations. Male and female patients
with mild/moderate asthma will be randomised to determine which order they receive a single
inhaled administration of GW685698X (800?g) with and without magnesium stearate. There will
be a wash-out period of at least 5 days between doses.